top of page

NCT-05996445

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination with Pembrolizumab in Advanced Solid Tumors


This medical study is designed to study XmAb 662, a new drug that is being developed to treat advanced solid tumors. The drug will be given to patients in two ways: either as a single agent (monotherapy) or in combination with pembrolizumab. Pembrolizumab is a type of immunotherapy drug called a PD-1 inhibitor. It works by blocking a protein called PD-1, which helps cancer cells evade the immune system. By blocking PD-1, pembrolizumab can help the immune system attack and kill cancer cells.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

NCT05996445

Clinical Trial Site: Sinai


To see all available clinical trials click here.



Recent Posts

See All

NCI-2022-06272

A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064

NCI-2019-04202

A Multi-Cohort Exploratory Study of Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC. Some patients have a tumor that is “resectable,” which means that it is able to be rem

NCI-2022-05056

Tislelizumab Consolidation after Liver-Directed Therapy for Hepatocellular Carcinoma (Phase II Study) This is a medical study to evaluate the safety and efficacy of tislelizumab in combination with ot

Comments


bottom of page